OLD National Bancorp IN Purchases 394 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

OLD National Bancorp IN raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,372 shares of the medical research company’s stock after purchasing an additional 394 shares during the quarter. OLD National Bancorp IN’s holdings in Thermo Fisher Scientific were worth $23,985,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TMO. Northwest Financial Advisors acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. True Wealth Design LLC grew its stake in Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after purchasing an additional 51 shares during the period. LifeSteps Financial Inc. acquired a new stake in Thermo Fisher Scientific during the first quarter worth approximately $31,000. Headlands Technologies LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth approximately $32,000. Finally, Bank & Trust Co acquired a new stake in Thermo Fisher Scientific during the second quarter worth approximately $33,000. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The disclosure for this sale can be found here. Insiders sold a total of 33,084 shares of company stock worth $19,767,092 over the last ninety days. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $3.86 during mid-day trading on Friday, hitting $596.18. The company had a trading volume of 939,843 shares, compared to its average volume of 1,561,510. The company has a market capitalization of $227.74 billion, a price-to-earnings ratio of 38.24, a P/E/G ratio of 2.80 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $622.30. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The stock’s 50-day moving average price is $568.11 and its 200-day moving average price is $569.84.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same period in the previous year, the business earned $5.15 earnings per share. The firm’s revenue was down 1.4% on a year-over-year basis. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.26%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Analyst Ratings Changes

Several equities research analysts recently commented on TMO shares. Raymond James raised their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Stifel Nicolaus raised their target price on Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a report on Thursday, July 25th. TD Cowen lifted their price target on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Robert W. Baird lifted their price target on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $618.94.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.